Acute myeloid leukaemia      

FOI REFERENCE: 24316    FOI DATE: 20^th August 2024   

Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period February 2024 to July 2024?

• Azacitidine monotherapy * patients
• Low dose cytarabine (LoDAC) monotherapy  * patients
• Venetoclax + azacitidine  40 patients
• Venetoclax + LoDAC 0 patients
• Ivosidenib  0 patients
• Intensive chemotherapy-based regimen
  • Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
  • cytarabine and daunorubicin * patients
  • gemtuzumab ozogamicin with daunorubicin cytarabine  11 patients
• Best supportive care
• Other
  • Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Note: this should only include patients with AML who have started first-line treatment during the 6-month window

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period February 2024 to July 2024
Azacitidine monotherapy	* patients
LoDAC monotherapy	0 patients
Venetoclax + azacitidine	40 patients
Venetoclax + LoDAC	0 patients
Ivosidenib	0 patient
Intensive chemotherapy-based regimen	cytarabine and daunorubicin * patients gemtuzumab ozogamicin with daunorubicin cytarabine  11patients
Best supportive care	0 patients
Other	0 patients

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018